D E Cohn


Affiliation: The Ohio State University
Country: USA


  1. Cohn D, Barnett J, Wenzel L, Monk B, Burger R, Straughn J, et al. A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. Gynecol Oncol. 2015;136:293-9 pubmed publisher
    ..Continued investigation of populations with ovarian cancer in whom the efficacy of treatment with bevacizumab is expected to be increased (or in whom QOL is expected to increase with use) is critical. ..
  2. Liang M, Elnaggar A, Nekkanti S, O Malley D, Hade E, Copeland L, et al. Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. Gynecol Oncol. 2015;138:689-93 pubmed publisher
    ..Increased attention to comprehensive surgical staging and timely initiation of chemotherapy appears warranted. With the move toward value-based payment models, quality indicators will play a significant role in health care delivery. ..
  3. Duska L, Java J, Cohn D, Burger R. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). Gynecol Oncol. 2015;139:221-7 pubmed publisher
    ..Readmissions are most likely after the initial surgical procedure, a discrete period to target with a prospective intervention. ..
  4. Cohn D, Hall N, Povoski S, Seamon L, Farrar W, Martin E. Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer. Gynecol Oncol. 2008;110:152-7 pubmed publisher
  5. Cohn D, Kim K, Resnick K, O Malley D, Straughn J. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol. 2011;29:1247-51 pubmed publisher
    ..Treatment with maintenance bevacizumab leads to improved PFS but is associated with both direct and indirect costs. The cost effectiveness of bevacizumab in the adjuvant treatment of ovarian cancer is primarily dependent on drug costs. ..
  6. Liang M, Rosen M, Rath K, Hade E, Clements A, Backes F, et al. Predicting inpatient stay lasting 2 midnights or longer after robotic surgery for endometrial cancer. J Minim Invasive Gynecol. 2015;22:583-9 pubmed publisher
    ..Recognition of factors predicting inpatient stay can improve hospital resource allocation and throughput in women undergoing robotic surgery for endometrial cancer. ..
  7. Cohn D, Havrilesky L, Osann K, Lipscomb J, Hsieh S, Walker J, et al. Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice. Gynecol Oncol. 2015;138:712-6 pubmed publisher
    ..Initial estimates of survival and adverse events associated with IP/IV chemotherapy differ among experts. The Delphi process works to build consensus and may be a pragmatic tool to inform patients of their expected outcomes. ..
  8. Neff R, Havrilesky L, Chino J, O Malley D, Cohn D. Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndrome. Gynecol Oncol. 2015;138:597-602 pubmed publisher
    ..WLS is a potentially cost-effective intervention in women with low risk, early stage EC, at least in part due to improved quality of life with weight reduction. ..
  9. Cohn D, Fabbri M, Valeri N, Alder H, Ivanov I, Liu C, et al. Comprehensive miRNA profiling of surgically staged endometrial cancer. Am J Obstet Gynecol. 2010;202:656.e1-8 pubmed publisher
    ..Endometrial cancer has a distinct miRNA profile, and miRNAs can be used as a predictive biomarker. ..

More Information


  1. Wallbillich J, Forde B, Havrilesky L, Cohn D. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecol Oncol. 2016;142:144-149 pubmed publisher
    ..However, reducing the cost of targeted therapy (independently, or in combination with reducing the cost of the genomic test) provides opportunities for improved value in cancer care. ..
  2. Cohn D, Backes F, Wallbillich J, Bixel K, Crafton S, Neff R, et al. Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. Gynecol Oncol. 2017;144:451-455 pubmed publisher
    ..The differential diagnosis, pathology, epidemiology, treatment options are discussed. Focus on the molecular pathways of LGSC and the implications of the diagnosis on fertility are highlighted. ..
  3. Mai P, Piedmonte M, Han P, Moser R, Walker J, Rodriguez G, et al. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;145:122-129 pubmed publisher
  4. Garcia Soto A, Java J, Nieves Neira W, Pearson J, Cohn D, Lele S, et al. Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol. 2016;143:484-489 pubmed publisher
    ..However, this was not found when only data from GOG 172 or GOG 114 were analyzed separately. Hence, the relationship between IP chemotherapy initiation and time from surgery needs to be studied further. ..
  5. Dilley S, Havrilesky L, Bakkum Gamez J, Cohn D, Michael Straughn J, Caughey A, et al. Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol. 2017;146:373-379 pubmed publisher
    ..In our model, salpingectomy was cost-effective with both procedures, but the advantage greater at time of hysterectomy. ..
  6. Cohn D, Sill M, Walker J, O Malley D, Nagel C, Rutledge T, et al. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;146:477-483 pubmed publisher
    ..The addition of reovirus to weekly paclitaxel in the treatment of women with recurrent or persistent ovarian, tubal or peritoneal cancer did not sufficiently reduce the hazard of progression or death to warrant further investigation. ..